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1452 | Med. Chem. Commun., 2013,Design, synthesis and antiproliferative activity of indole
analogues of indanocine†
Gemma A. Tunbridge, Joseph Oram and Lorenzo Caggiano*
The design and synthesis of a novel series of indole-analogues of indanocine is reported, together with
their antiproliferative activity in the NCI's panel of cancer cell lines. Indanocine displays potent activity
against a wide range of cancer cell lines (mean GI50 < 20 nM), including drug-resistant cancer cell lines,
and also inhibits the migration of metastatic cancer cells. A number of the described indole-analogues
display a similar activity proﬁle to indanocine, exhibiting potent antiproliferative activities in several
cancer cell lines, and oﬀer new leads for further development.Introduction
Continuing our interest in compounds that interact with
tubulin,1,2 we wished to investigate novel analogues of inda-
nocine 1 (Fig. 1). Indanocine 1 is a substituted indanone that
displays potent antiproliferative activity against tumour cell
lines (mean GI50 < 20 nM, the mean concentration to inhibit
50% cell growth against the National Cancer Institute's (NCI)
panel of cancer cell lines), and is also active against
multidrug resistant cell lines.3–5 Drug resistance can be due
to several factors, including overexpression of the P-glyco-
protein drug eﬄux pump,6 and studies have shown that
although tumour cells which overexpress the 170 kD
P-glycoprotein are resistant to paclitaxel, they remain sensi-
tive to indanocine 1.4
Indanocine 1 is a potent microtubule-destabilizing agent
and binds to the colchicine binding site of tubulin.7–9 Recent
reports have shown that indanocine reduces dynamic instability
of microtubules at low concentrations and inhibits migration of
metastatic cancer cells.10 Therefore indanocine and associated
analogues are of great interest as they not only have promise as
potential chemotherapeutic agents,11 but could also be used to
prevent the spread of cancer through metastasis.
Various indanocine analogues have been previously repor-
ted,5,12–16 however, we wished to apply an approach previously
reported by Hudlicky et al. in the design of pancratistatin
analogue 3 (Fig. 1).17 Isolated by Pettit et al.,18 pancratistatin 2 is
a natural product which exhibits potent anticancer activity,19
and shows excellent promise as a therapeutic drug, particularly
in brain cancers.20 Hudlicky et al. proposed that the indolecy and Pharmacology, University of Bath,
l.caggiano@bath.ac.uk; Fax: +44 (0)1225
SI) available: Experimental procedures,
spectra, and COMPARE analyses of
39/c3md00200d
4, 1452–1456motif has similar steric and electronic properties to the 4-
hydroxy-benzo[1,3]dioxole group present in pancratistatin 2
(highlighted in bold, Fig. 1).17 In addition, the indole analogue 3
also retains the hydrogen-bonding pattern of the natural
product 2, believed to be important for potency.
Following this work,17 and the success of other indole-based
inhibitors of tubulin polymerisation,21 we wished to investigate
if the indole motif would also be a suitable bioisostere for the
dimethoxyaniline group present in indanocine 1 (highlighted in
bold, Fig. 2). We now describe the synthesis and anti-
proliferative activity of indole-analogues of indanocine (4 and 5)
outlined in Fig. 3. We wished to investigate both the 5-
membered ring cyclic ketone (4, as found in indanocine 1) and
the corresponding 6-membered ring core (5), since indanones5
and tetralones14,15,22 of similar compounds were both found to
be the most active. In addition, the eﬀects of the N–H hydrogenFig. 1 Structures of indanocine 1, pancratistatin 2 and an indole-analogue of
pancratistatin 3.
This journal is ª The Royal Society of Chemistry 2013
Fig. 3 Indole analogues of indanocine 4 and 5.
Scheme 1 Synthesis of the indole-analogues 4a–h and 5a–h. (i) PPA (6) or TFAA (7). (ii) KOH/MeI, acetone (iii) See Table 1.
Fig. 2 Proposed indole-analogues of indanocine.
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View Article Onlinebonding interaction (R1¼H, a–d and R1¼Me, e–h) and various
substituted aryl rings (R2 ¼Me or OMe and R3 ¼ H or OH) were
also investigated (see Table 1).Table 1 Yields and NSC numbers of indole analogues 4 and 5 (Fig. 3)
Comp. R1 R2 R3 n Cond.a Yield (%) NSCb
4a H Me H 1 A 72 ns
4b H OMe H 1 A 73 ns
4c H Me OH 1 B 61 756 592
4d H OMe OH 1 B 54 756 591
4e Me Me H 1 A 45 ns
4f Me OMe H 1 A 12 —
4g Me Me OH 1 B 3 ns
4h Me OMe OH 1 B 49 ns
5a H Me H 2 C 29 756 584
5b H OMe H 2 C 47 756 585
5c H Me OH 2 D 21 756 586
5d H OMe OH 2 D 33 756 587
5e Me Me H 2 C 55 756 588
5f Me OMe H 2 C 26 756 589
5g Me Me OH 2 D 11 756 590
5h Me OMe OH 2 D — —
a Reaction conditions for Step (iii) in Scheme 1: A ¼ KOH/EtOH, rt;25,26 B
¼ KOH/methoxyethanol, 120 C; C ¼ LiOH/H2O/EtOH;27 D ¼ BF3$OEt2,
dioxane.28 b NCI's National Service Center (NSC) number; ns ¼ not
selected by the NCI.
This journal is ª The Royal Society of Chemistry 2013Results and discussion
The synthesis of the analogues is shown in Scheme 1 and the
yields and conditions in Table 1. Commercially available 3-
indolepropionic acid (6) or 3-indolebutyric acid (7) were treated
with PPA23 or TFAA, respectively, to aﬀord the corresponding
cyclic ketone 8 (81%) or 9 (72%, Step i, Scheme 1).
Following previously reported procedures,23,24 methyla-
tion of the indole nitrogen was readily achieved using KOH/
MeI, aﬀording the N–Me derivatives 10 (95%) and 11 (92%,
Step ii). Finally, the cyclic ketones 8–11 underwent Claisen–
Schmidt condensation with the required aldehyde in the
presence of base or Lewis acid to give the indole-analogues
4a–h and 5a–g, as shown in Scheme 1 (Step iii) and Table 1.
Owing to capricious results, several reaction conditions were
used in this transformation,25–28 which are described in the
ESI.†
Only the E-isomers were obtained from the Claisen–Schmidt
condensation reaction, as identied by the characteristic
downeld shi of the COC]CH proton, due to a deshielding
eﬀect caused by diamagnetic anisotropy by the C]O which is
cis to this proton, as previously noted.29 This assignment was
conrmed by key NOESY interactions (see ESI† compounds 5c
and 5g) and is consistent with observations made with this
reaction in similar substrates which also gave the E-
isomers.13–15,22,30
4-Hydroxy-3,5-dimethylbenzaldehyde and the corresponding
3,5-dimethoxy derivative, syringaldehyde, were investigated as
although the former aldehyde gave the substitution pattern
observed in indanocine (R2 ¼ Me, Fig. 3), the latter is readily
available and inexpensive.
Nine compounds were selected for one-dose preliminary
in vitro evaluation at 10 mM by the NCI (those with NSC
numbers in Table 1). Five of these compounds (4c, 5a–c andMed. Chem. Commun., 2013, 4, 1452–1456 | 1453
Table 2 Growth inhibition of indanocine 1 and selected analogues 4c, 5c and
5g in the NCI 60 panel of cancer cell lines
Panel Cell line
GI50 (mM)
a
1 4c 5c 5g
Leukemia CCRF-CEM 0.01 2.18 0.36 0.74
HL-60(TB) 0.01 0.34b 0.21b 0.34b
K-562 0.01 0.33b 0.32b 0.33b
MOLT-4 0.01 6.01 0.56 0.80
RPMI-8226 0.01 0.67 0.47 0.76
SR 0.01 0.39 0.22 0.34
Non-Small A549/ATCC 0.01 1.58b 0.55b 0.74b
Cell Lung EKVX 0.01 2.59 3.38 4.84
HOP-62 0.02 0.65 0.65 0.72
HOP-92 100 7.47 0.78 6.56
NCI-H226 3.98 9.60 3.29 4.38
NCI-H23 0.01 1.79b 0.65b 2.53b
NCI-H322M 0.01 10.4 0.53 2.73
NCI-H460 0.01 0.42 0.41 0.39
NCI-H522 0.01 0.09 0.13 0.14
Colon COLO 205 5.01 19.5 14.2 22.9
HCC-2998 2.00 7.49 2.21 3.61
HCT-116 0.01 0.50 0.44 0.39
HCT-15 0.01 0.56 0.42 0.51
HT29 2.51 15.8 4.32 4.18
KM12 0.01 0.46 0.39 0.45
SW-620 0.01 0.41 0.41 0.43
CNS SF-268 0.01 0.86 0.73 0.72
SF-295 0.06 2.78 1.88 1.48
SF-539 0.01 0.55 0.32 0.70
SNB-19 0.01 0.71 0.58 0.63
SNB-75 — 0.29 0.29 0.41
U251 0.02 1.12 0.43 0.54
Melanoma LOX IMVI 0.01 0.69 0.76 0.70
MALME-3M — 0.31b 0.38 0.45
M14 0.01 0.41 0.34 0.39
MDA-MB-435 0.01 0.16 0.12 0.16
SK-MEL-2 1.00 0.40 0.32 0.33
SK-MEL-28 1.00 0.73b 0.74 0.64
SK-MEL-5 0.01 0.39 0.33 0.41
UACC-257 100 26.1 0.37 5.83
UACC-62 0.01 4.57 0.42 0.41
Ovarian IGROV1 0.04 3.54 0.74 1.59
OVCAR-3 0.01 0.51 0.33 0.35
OVCAR-4 7.94 10.2 1.35 3.87
OVCAR-5 0.63 11.1 2.35 5.10
OVCAR-8 0.01 0.99 0.53 0.92
NCI/ADR-RES 0.01 0.35 0.31 0.34
SK-OV-3 0.01 0.73 0.47 1.52
Renal 786-0 0.01 5.96 0.88 3.25
A498 7.94 4.86 1.83 3.39
ACHN 0.06 — 0.77 0.83
CAKI-1 3.98 1.40 0.61 0.84
RXF 393 0.03 1.43 0.52 1.08
SN12C 0.01 0.62 0.62 0.72
TK-10 79.4 6.27b 0.54b 1.08b
UO-31 0.08 0.32 0.45 0.73
Prostate PC-3 0.01 3.57 1.06 2.49
DU-145 0.01 2.05 0.54 1.85
Breast MCF7 0.01 0.70 0.35 0.37
MDA-MB-231/ATCC 0.01 3.19 1.06 1.06
Table 2 (Contd. )
Panel Cell line
GI50 (mM)
a
1 4c 5c 5g
HS 578T — 0.55 0.38 0.73
BT-549 10 — 0.53 2.84
T-47D 100 12.6 0.74 2.06
MDA-MB-468 — 2.43 0.29 0.31
a GI50 is concentration required to inhibit growth by 50% as dened by
the National Cancer Institute (NCI). Values for 4c, 5c and 5g are the
average of two runs, except b one run.
1454 | Med. Chem. Commun., 2013, 4, 1452–1456
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View Article Online5g) were selected for further examination at ve-doses. Three
of these ve analogues were selected for a repeat screen (4c, 5c
and 5g) and the results obtained are shown in Table 2, as the
average of these two runs, together with indanocine 1 for
comparison.
Indanocine 1 is extremely potent cell growth inhibitor, dis-
playing 10 nM activity against many of the cell lines examined
by the NCI. Although our analogues display decreased activities,
they retain useful levels of potency in the low sub-micromolar
range.
From Table 2, it is apparent that certain cells types appear
particularly sensitive to the indole-analogues, such asNon-Small
Cell Lung NCI-H522 cell line (GI50 ¼ 93 nM, 4c) and Melanoma
MDA-MB-435 cells (GI50¼ 120 nM, 5c). Of particular note is that
all three analogues display sub-micromolar growth inhibition
against the multi-drug resistant NCI/ADR-RES cell line. Other
cell lines, however, appear more resilient to the analogues
which are also reected in indanocine 1, such as the Melanoma
cell line UACC-257 (GI50 ¼ 100 mM, 1, and 26.1 mM, 4c). Inter-
estingly, the cyclohexanone N–H derivative 5c still retains
activity in this cell line (GI50 ¼ 370 nM). Likewise similar
discrepancies with compound 5c are also observed in Renal TK-
10 and Breast T-47D cell lines.
Of the compounds synthesized and examined in this study,
the most active antiproliferative analogues are those most
similar in structure to indanocine, as predicted in Fig. 2. They
all possess a benzylidene with a hydroxyl group (R3), anked
either side with methyl groups (R2); methoxy groups at R2 were
detrimental to activity. These observations are consistent with
previously established SAR around the benzylidene ring5 and
calculations used to identify important pharmacophoric points
for indanocine.31
Methylation of the indole nitrogen (R1) was tolerated in the
6-membered ring series (5), as both the N–H (5c) and N–Me (5g)
analogues displayed good activities (Table 2). Although the 5-
membered ring N–H analogue 4c was active, the corresponding
N–Me derivative 4g was not selected by the NCI, so a compar-
ison cannot be made. These results suggest that although
changes to the aryl group are not tolerated, indole N-substitu-
tion is and demonstrate that further modications around the
indole ring, as observed in many indole-based tubulin inhibi-
tors,21 should be investigated in future.This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineFrom the nal three analogues, the cyclopentanone
derivative 4c was selected by the NCI for consideration by the
Biological Evaluation Committee and has been classied as a
tubulin binder. COMPARE analysis32,33 of the lead compound
4c using the standard algorithm with Synthetic Compounds
gave the strongest correlation (0.795) with centaureidin
(NSC 106969), a natural product isolated from the tropical
plant Polymnia fruticosa which exhibits antiproliferative
activity through the inhibition of tubulin polymerisation.34,35
Other compounds identied by the COMPARE algorithm
included several combretastatin derivatives (see ESI†), which
are also tubulin-binding agents and, like indanocine 1,
similarly interact with the colchicine binding site and inhibits
tubulin polymerisation.36 Of particular note is that the lead
compound 4c also displayed good correlation (0.646, rank 26)
with indanocine 1 (NSC 698666). Of interest is that although
combretastatin derivatives were also observed in the
COMPARE analyses of both compounds 5c and 5g, only the
cyclohexanone N–Me analogue 5g showed any signicant
correlation with indanocine 1 (0.593, rank 108) as the cyclo-
hexanone N–H derivative 5c displayed poor correlation
(0.426, rank 707).Conclusions
In summary, we report that the indole group is an eﬀective
bioisostere for the dimethoxyaniline motif present in indano-
cine 1 and describe the synthesis of several indole-based
analogues, in either two or three steps from commercially
available materials. Several of these compounds were selected
for evaluation by the National Cancer Institute (NCI) and anal-
ysis using the COMPARE algorithm show that our strategy was
successful and that we have identied a novel class of
compounds which, like indanocine 1, interact with tubulin and
display potent antiproliferative activity against various cancer
cell lines including drug-resistant cells.
Although “indolocine” 4c is less potent than indanocine 1,
the indole group oﬀers a versatile platform to generate further
derivatives with more desirable physicochemical properties and
target enhanced potency and selectivity. Such compounds could
nd potential as novel chemotherapeutic agents to combat
cancer or prevent its spread by inhibiting the migration of
metastatic cancer cells and will be investigated and reported in
due course.Acknowledgements
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